Renalytix Share Discussion Threads

[the stigologist] 04/10/2020 14:55

If anything the need for quarterly reporting just makes Companies more circumspect on reporting more expansively on forward looking outlook

[tawnyport] 04/10/2020 12:45

The Verici roadshow begins this week so that should also help in reminding investors of the potential in this business during the story-telling process. Looking forward to the share price rise in the next few days.

[mr roper] 02/10/2020 17:57

UP 6% Stateside so far. Suspect it’ll now track back towards the listing price and take direction from the next news. End of Q1 I suspect we’ll be nearer 1000p than 500p

[74tom] 01/10/2020 14:04

Received a response to my queries re. results & Kantaro comms this morning, postive that we'll get quarterly reporting from now onwards - I've always preferred the US system compared to AIM where company can sometimes go almost a year without publishing financials!

"As the Company’s fiscal year ends June 30th, RenalytixAI is issuing an Annual Report which will be out in mid-October vs. an interim report. Going forward, now that the Company is listed on NASDAQ, it will be reporting on a quarterly basis."

"Kantaro continues to make progress and we would expect the Company to issue an update in the near future. The NYS DOH quantitative approval was issued for the Mount Sinai laboratory developed test – an important milestone. The Kantaro testing kit is running a separate regulatory review process."

[mr roper] 01/10/2020 08:10

Looks like a pretty standard walk down to test the 200ma, thin volume and quiet on the the big news for the last 4 weeks. Suspect the next 4 weeks may show something of a reversal in the trend

[wan] 01/10/2020 07:53

Any fear over the time taken and Kantaro's efforts regarding the antibody test do not appear well founded in my opinion. Plus, Renalytix just tweeted the following -

We're committed to the fight against #COVID19. We've employed our scientific resources & #technology to support continued efforts to protect patients & stop the spread of this disease on multiple fronts. Read more about our ongoing #COVID efforts here:

[74tom] 30/9/2020 21:21

That’s a pleasant surprise, closed at the equivalent of £4.72, so should be a decent bounce tomorrow...

[faz] 30/9/2020 20:52

Decent volume and we're up 20% on Nasdaq (20.50), Maybe someone over there read the prospectus.

[mr roper] 30/9/2020 16:32

10% bounce Stateside. Would think renx benefits from either Trump or Biden victory.

[74tom] 30/9/2020 14:33

Yes I think it's at least part of the reason, it's a very illiquid share though which emphasises sentiment in both directions. Clearly KideyIntelX is the most important facet and it's great to see the continued progress there, but there will have been a decent number of investors who bought in for the Covid angle. Bottom line is they would have been better not announcing it at all if they had no intention of following up... All will hopefully be revealed in due course.

[nimbo1] 30/9/2020 14:04

Yes results should not be that hard to piece together given it was a 0 revenue period!

[digger18] 30/9/2020 13:32

I wonder if this is one of the reasons the share price has tanked? Certainly not helping and now way below the global offer price.

[74tom] 30/9/2020 13:30

No idea Digger18. I actually sent an email to investor relations this morning to enquire about that & the interims to 30th June. Will let you know if I get any response... 4.5 months without updating the market is a little bit silly + the Kantaro website still says release at scale in August which is clearly wrong.

[digger18] 30/9/2020 10:59

What is the latest situation with the Kantaro Covid antibody test? Originally supposed to launch into market at the end of July and then put back to end of August?
I can’t find anything to confirm the current status?

[nimbo1] 29/9/2020 20:08

Yes isn’t pretty currently but will be a very good op for new buyers. Question is where - maybe Volsung is right but I hope not.

[74tom] 29/9/2020 17:31

NASDAQ is remorselessly dropping the price at present, undoubtedly some shorting going on over there alongside low volume...would take a brave US investor to buy that trend at present. EV is now around £225m assuming they have £70m of cash, this is the same level as the 2019 high of £3.80. Crazy times.

[cambridgedon] 29/9/2020 15:10

Picked up some more as it bounced off 200MA. Hope it holds here.
CD

[the stigologist] 29/9/2020 15:01

Yes was a quite well defined Head and Shoulders pattern which I guess 74tim spotted and sold on

[volsung] 29/9/2020 11:41

I will think about buying at 300p. That's what the chart is saying

[the stigologist] 28/9/2020 22:38

Looks like Tom74 has sold some here and has moved it to AGL given he's talking about RENX there?

And he gave me grief for talking about PYC here !

[the stigologist] 24/9/2020 22:08

In the mean time check out relatively undiscovered UK Cancer AI player Physiomics PYC

Mkt Cap £8m with Rev of c.£1m

vs

RENX

Mkt Cap £400m with Rev of c.£0m


Chartwise PYC is on a steady medium term uptrend with occasional superspikes up

[74tom] 24/9/2020 22:01

Fair play, personally I’m not buying more until NASDAQ settles down, these 4% daily drops on tiny volume vs market cap are eroding the price at a rate of knots... I wonder if we are being punished due to recent goings on at Nikola & Nano-X imaging. Both are pre revenue & I can imagine any US investors who bought RENX after its IPO must be unnerved by its 25% fall, whilst potential new comers avoid a falling knife...

Brighter times will return of course and I completely agree with Charlieej, this will be significantly higher by Xmas.

[nimbo1] 24/9/2020 16:26

Bought some and will buy more at the 200 dma if it goes there - nasdaq really punishing it today! great long term opportunity I hope

[charlieej] 24/9/2020 16:21

They have significant cash, should have FDA approval this year, will have a share in the first test to give levels of antibodies (when finally approved) hopefully soon, and on top of which there are sure to be plenty of deals being worked on in the background. I'd be amazed if it's not significantly higher by Christmas. The company has not failed to deliver on anything bar the antibody test which they are only a minority shareholder in and it was always brave to try and predict the FDA turnaround time on a new form of test. This isn't particularly liquid so down moves and up moves will be exaggerated.